Automatic Evaluation of Test Strips for Anti-Ganglioside Antibodies in Patients with Guillain-Barré Syndrome Using EUROLineScan Software

Abstract Full-Text HTML Download Download as PDF (Size:2746KB) PP. 890-898
DOI: 10.4236/aim.2014.413099    3,161 Downloads   3,826 Views  

ABSTRACT

Campylobacter jejuni infection has been implicated in the pathogenesis of Guillain-Barré syndrome (GBS) due to production of humoral immune response against neural antigens. A case-control study was performed in a tertiary care teaching hospital for the estimation of anti-ganglioside antibodies in GBS patients and their controls. Blood samples were collected from 59 GBS cases, 58 neurological controls (NC) and 60 non-neurological control (NNC) patients for automatic estimation of IgG and IgM antibodies to seven gangliosides using EUROLineScan software. Antibodies of IgG class for GM1 were highly significant in GBS (p = 0.000) and NC (p = 0.031) compared to NNC. However GBS group was not significant (p = 0.413) compared to NC. For GM2 ganglioside, GBS and NC groups were significant (p = 0.000) compared to NNC, but GBS group was not significant (p = 0.999) compared to NC. For GM3 ganglioside, GBS and NC groups were significant (p = 0.000) compared to NNC; but GBS group was insignificant (p = 0.858) compared to NC with similar trend for all other ganglioside antibodies. When IgM class of antibodies was evaluated for GM1, GBS group was not significant (p = 0.604) whereas NC group was significant (p = 0.000) compared to NNC. GBS group was not significant compared to NC (p = 0.011). The trend was the same for GM2 antibodies. For GM3, GBS group was significant (p = 0.010) and NC was near significant (p = 0.055) compared to NNC. However GBS group was not significant (p = 0.808) compared to NC. No groups were significant (p > 0.05) in relation to the remaining gangliosides except for GQ1b where GBS group (p = 0.001) and NC group were significant (p = 0.000) compared to NNC. GBS group was also significant (p = 0.001) compared to NC and NNC. Anti-gangliosides antibodies were present in highly significant levels in the GBS group, though they were also present in the non-paralytic neurological control patients compared to the non-neurological control group.

Cite this paper

Vaishnavi, C. , Behura, C. and Prabhakar, S. (2014) Automatic Evaluation of Test Strips for Anti-Ganglioside Antibodies in Patients with Guillain-Barré Syndrome Using EUROLineScan Software. Advances in Microbiology, 4, 890-898. doi: 10.4236/aim.2014.413099.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Hughes, R.A.C., Cornblath, D.R. (2005) Guillain-Barré Syndrome. Lancet, 366, 1653-1666.
http://dx.doi.org/10.1016/S0140-6736(05)67665-9
[2] Kinnunen, E., Junttila, O., Haukka, J. and Hovi, T. (1998) Nationwide Oral Poliovirus Vaccination Campaign and the Incidence of Guillain-Barré Syndrome. American Journal of Epidemiology, 147, 69-73. http://dx.doi.org/10.1093/oxfordjournals.aje.a009369
[3] Rees, J. and Hughes, R. (1994) Guillain-Barré Syndrome after Measles, Mumps and Rubella Vaccine (Letter; Comment). Lancet, 343, 733. http://dx.doi.org/10.1016/S0140-6736(94)91614-4
[4] Newton, N. and Janati, A. (1987) Guillain-Barré Syndrome after Vaccination with Purified Tetanus Toxoid. Southern Medical Journal, 80, 1053-1054. http://dx.doi.org/10.1097/00007611-198708000-00028
[5] Winer, J.B., Hughes, R.A.C., Anderson, M.J., Jones, D.M., Kangro, H. and Watkins, R.P.F. (1998) A Prospective Study of Acute Idiopathic Neuropathy. II. Antecedent Events. Journal of Neurology, Neurosurgery & Psychiatry, 51, 613-618. http://dx.doi.org/10.1136/jnnp.51.5.613
[6] Rhodes, K.M. and Tattersfield, A.E. (1982) Guillain-Barré Syndrome Associated with Campylobacter Infection (Letter). British Medical Journal, 285, 652. http://dx.doi.org/10.1136/bmj.285.6336.173
[7] Kuroki, S., Saida, T., Masafumi, N., et al. (1993) Campylobacter jejuni Strains from Patients with Guillain-Barré Syndrome Belong Mostly to Penner Serogroup 19 and Contain β-N-acetylglucosamine Residues. Annals of Neurology, 33, 243-247. http://dx.doi.org/10.1002/ana.410330304
[8] Kaldor, J. and Speed, B.R. (1984) Guillain-Barré Syndrome and Campylobacter jejuni: A Serological Study. British Medical Journal, 288, 1867-1870. http://dx.doi.org/10.1136/bmj.288.6434.1867
[9] Heidenreich, F. (1998) Autoantibodies Associated with Peripheral Neuropathies. In Conrad, K., et al., Eds., Pathogenic and Diagnostic Relevance of Autoantibodies. Report on the 4th Dresden Symposium on Autoantibodies Held in Dresden on 21-24 October 1998, Pabst Science Publishers, Lengerich.
[10] Pestronk, A. and Choksi, R. (1997) Multifocal Motor Neuropathy: Serum IgM anti-GM1 Ganglioside Antibodies in Most Patients Detected Using Covalent Linkage of GM1 to ELISA Plates. Neurology, 49, 1289-1292. http://dx.doi.org/10.1212/WNL.49.5.1289
[11] Daune, G.D., Farrer, R.G. and Dalakas, M.C. (1992) Sensory Neuropathy Associated with Monoclonal Immunoglobulin M to GD1b Ganglioside. Annals of Neurology, 31, 683-685.
http://dx.doi.org/10.1002/ana.410310621
[12] Vaishnavi, C., Behura, C., Prabhakar, S., Sharma, A. and Kharbhanda, P. (2013) Anti-Ganglioside Antibodies in Patients with Guillain-Barré Syndrome and Other Neurological Disorders. Indian Journal of Medical Microbiology, 31, 177-179.
[13] Asbury, A.K. and Cornblath, D.R. (1990) Assessment of Current Diagnostic Criteria for Guillain-Barré Syndrome. Annals of Neurology, 27, S21-S24. http://dx.doi.org/10.1002/ana.410270707
[14] Meyer, W., Schneider, B., Nobile, Orazio, E., Klotz, M., Schlumberger, W. and Stocker, W. (2002) EUROLINE Anti-Ganglioside-Profile: A New Membrane Test for Detection of Antibodies against Gangliosides. Autoimmunity Reviews, 1, 71.
[15] Osterman, P.O., Lundemo, G., Pirskanen, R., Fagius, J., Pihlstedt, P. and Siden, A. (1984) Beneficial Effects of Plasma Exchange in Acute Inflammatory Polyradiculoneuropathy. The Lancet, 2, 1296-1298. http://dx.doi.org/10.1016/S0140-6736(84)90819-5
[16] Gorenjac, M. (2004) Clinical and Diagnostic Role of Ganglioside Antibody Testing. Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 15, Article ID: 150309.
[17] Nobuhiro, Y., Taki, T., Inagaki, F., Kasama, T., Takahashi, M., Saito, K., et al. (1993) A Bacterium Lipopolysaccharide That Elicits Guillain-Barré Syndrome Has a GM1 Ganglioside-Like Structure. The Journal of Experimental Medicine, 178, 1771-1775. http://dx.doi.org/10.1084/jem.178.5.1771
[18] Yuki, N. and Odada, M. (2005) Ganglioside Mimicry as a Cause of Guillain-Barré Syndrome. Current Opinion in Neurology, 18, 557-561. http://dx.doi.org/10.1097/01.wco.0000174604.42272.2d
[19] Dikmen, P.Y. and Oge, A.E. (2012) Recurrent GBS with GD1a Anti-Ganglioside Antibodies. Journal of the Peripheral Nervous System, 17, 135-137. http://dx.doi.org/10.1111/j.1529-8027.2012.00384.x
[20] Taheraghdam, A., Pourkhanjar, P., Talebi, M., Bonyadi, M., Pashapour, A., Sharifipour, E., et al. (2014) Correlations between Cytomegalovirus, Epstein-Barr Virus, Anti-Ganglioside Antibodies, Electrodiagnostic Findings and Functional Status in Guillain-Barré Syndrome. Iranian Journal of Neurology, 13, 7-12.
[21] Goddard, E.A., Lastovica, A.J. and Argent, A.C. (1997) Campylobacter 0:41 Isolation in Guillain-Barré Syndrome. Archives of Disease in Childhood, 76, 526-528. http://dx.doi.org/10.1136/adc.76.6.526
[22] Takahashi, M., Koga, M., Yokoyama, K. and Yuki, N. (2005) Epidemiology of Campylobacter jejuni Isolated Guillain-Barré and Fisher Syndrome in Japan. Journal of Clinical Microbiology, 43, 335-339. http://dx.doi.org/10.1128/JCM.43.1.335-339.2005
[23] Koga, M., Gilbert, M., Takahashi, M., et al. (2006) Comprehensive Analysis of Bacterial Risk Factors for the Development of Guillain-Barré Syndrome after Campylobacter jejuni Enteritis. The Journal of Infectious Diseases, 193, 547-555. http://dx.doi.org/10.1086/499969
[24] Godschalk, P.C.R., Heikema, A.P., Gilbert, M., et al. (2004) The Crucial Role of Campylobacter jejuni Genes in Autoimmune Antibody Induction. Journal of Clinical Investigation, 114, 1659-1665.
http://dx.doi.org/10.1172/JCI200415707
[25] Saida, T., Kuroki, S., Hao, Q., Nishimura, M., Nukina, M. and Obayashi, H. (1997) Campylobacter jejuni Isolates from Japanese Species with Guillain-Barré Syndrome. The Journal of Infectious Diseases, 176, S129-S134. http://dx.doi.org/10.1086/513798
[26] Kaur, U., Chopra, J.S., Prabhakar, S., Radhakrishnan, K. and Rana, S. (1986) Guillain-Barré Syndrome: A Clinical Electrophysiological and Biochemical Study. Acta Neurologica Scandinavica, 73, 394-402. http://dx.doi.org/10.1111/j.1600-0404.1986.tb03295.x
[27] Vaishnavi, C. (2001) Campylobacter Enteritis and Extraintestinal Complications. Gastroenterology Today, 4, 189-191.
[28] Hughes, R.A. and Rees, J.H. (1997) Clinical and Epidemiologic Features of Guillain-Barré Syndrome. The Journal of Infectious Diseases, 176, S92-S98. http://dx.doi.org/10.1086/513793
[29] Hadden, R.D. and Gregson, N.A. (2001) Guillain-Barré Syndrome and Campylobacter jejuni Infection. Journal of Applied Microbiology, 90, S145-S154. http://dx.doi.org/10.1046/j.1365-2672.2001.01363.x
[30] Pradhan, S., Sinha, S., Prasad, N., Jain, D., Pandey, C.M. and Jha, S. (2007) Preceding Infections and Anti-Ganglioside Antibodies in Patients with Guillain-Barré Syndrome: A Single Centre Prospective Case-Control Study. Clinical Microbiology and Infection, 13, 334-337.
http://dx.doi.org/10.1111/j.1469-0691.2006.01636.x
[31] Sharma, A., Lal, V., Modi, M., Vaishnavi, C. and Prabhakar, S. (2011) Campylobacter jejuni Infection in Guillain-Barré Syndrome; A Prospective Case Control Study in a Tertiary Care Hospital. Neurology India, 59, 717-721. http://dx.doi.org/10.4103/0028-3886.86547
[32] Schmidt-Ott, R., Schmidt, H., Feldmann, S., Brass, F., Krone, B. and Gross, U. (2006) Improved Serological Diagnosis Stresses the Major Role of Campylobacter jejuni in Triggering Guillain-Barré Syndrome. Clinical and Vaccine Immunology, 13, 779-783. http://dx.doi.org/10.1128/CVI.00065-06
[33] Fugimoto, S. and Amako, K. (1990) Guillain-Barré Syndrome and Campylobacter jejuni Infection. The Lancet, 335, 1350. http://dx.doi.org/10.1016/0140-6736(90)91234-2
[34] McCarthy, N. and Giesecke, J. (2001) Incidence of Guillain-Barré Syndrome Following Infection with Campylobacter jejuni. American Journal of Epidemiology, 153, 610-614.
http://dx.doi.org/10.1093/aje/153.6.610
[35] Kuwabara, S. (2004) Guillain-Barré Syndrome: Epidemiology, Pathophysiology and Management. Drugs, 64, 597-610. http://dx.doi.org/10.2165/00003495-200464060-00003
[36] Li, C.Y., Xue, P., Tian, W.Q., Liu, R.C. and Yang, C. (1996) Experimental Campylobacter jejuni Infection
in the Chicken: An Animal Model of Axonal Guillain-Barré Syndrome. Journal of Neurology, Neurosurg-
ery Psychiatry, 61, 279-284. http://dx.doi.org/10.1136/jnnp.61.3.279

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.